When facing a post prostatectomy biochemical failure (PSA only failure) the best way to treat is still not known. Preliminary data from Johns Hopkins [1] and Duke Universities[2] have recently provided some of the earliest evidence that salvage radiotherapy may prolong overall survival versus delay of intervention until time of symptomatic progression. Despite [...]
The big news from yesterday is that the Food and Drug Administration (FDA) has approved a MRI-guided, focused ultrasound therapy for the treatment of bone pain associated with metastatic advanced prostate cancer. In a media release written by InSight, an Israeli company states that its ExAblate® MRI-guided, focused ultrasound technology is indicated to treat pain [...]
A recently published article in Urology Times claims that salvage high-intensity focused ultrasound (HIFU) appears to be an effective treatment option for locally recurrent prostate cancer after primary external beam radiation therapy (EBRT) failure. The study, which this article reported on, used data from analyses of 6-year oncologic outcomes show. When the researchers did a [...]
Can brachytherapy be a reasonable salvage option for men with a local recurrence after the failure of initial radiotherapy for prostate cancer treatment? A recent review of the literature evaluated the use of radiation as a salvage option after the failure of local-only treatment with radiation. The results were mixed. The researchers did a PubMed [...]
Men with locally advanced prostate cancer have a better survival chance if they receive radiotherapy along with androgen deprivation therapy (ADT). This data was presented at the recent American Society of Clinical Oncology (ASCO) 2012 conference. Professor Malcom Mason from Whales University discussed a trial he conducted that demonstrated that for a man diagnosed with [...]
In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]
A group of researchers just reported positive results of a phase 3 trial showing that the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer (T3 & T4) to androgen deprivation therapy (ADT) alone. The researchers used a sample of 1,057 men with locally advanced (T3 or T4) prostate [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]
Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer. […]
In prior studies with men who have had a PSA recurrence after radiotherapy (RT), intermittent androgen suppression (IAS) has been suggested to improve quality of life (QoL) but effects on survival are unknown. The researchers performed an inter-group randomized phase III trial, which compared IAS vs continuous androgen deprivation (CAD) to test overall survival (OS) [...]
